Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule

DF5112 provides deep Th17 and B cell depletion in IV cohort and is now dosing its Phase 1 subcutaneous cohorts. WALTHAM, Mass., May 18, 2026 /PRNewswire/ -- Dragonfly Therapeutics, a clinical-stage biopharmaceutical company pioneering novel immunotherapies, today announced that the first...